Download PDF
Pneumologie 2003; 57(8): 449-458
DOI: 10.1055/s-2003-41550
Serie: Update Erreger von Atemwegsinfektionen (3)
© Georg Thieme Verlag Stuttgart · New York

Klinisches Bild, Diagnostik und Therapie der Chlamydien-Pneumonie

Clinical Picture, Diagnosis and Treatment of Chlamydia PneumoniaO.  Burkhardt1 , E.  Straube2 , T.  Welte1
  • 1Abteilung für Pneumologie und Internistische Intensivtherapie (Leiter: Priv.-Doz. Dr. med. T. Welte), Medizinische Fakultät der Otto-von-Guericke-Universität Magdeburg
  • 2Institut für Medizinische Mikrobiologie (Leiter: Prof. Dr. med. E. Straube), Friedrich-Schiller-Universität Jena
Further Information

Publication History

Publication Date:
29 April 2004 (online)

Also available at
   Permissions and Reprints

Einleitung

In den letzten Jahren wurde mehrfach über einen kontinuierlichen Wandel im Erregerspektrum der ambulant erworbenen Pneumonie berichtet. Hierbei zeigte sich der allgemeine Trend einer relativen Zunahme so genannter atypischer Pneumonieerreger bei gleichzeitigem Rückgang grampositiver Mikroorganismen [1] [2] [3] [4] [5] [6] [7] [8]. Zu diesen atypischen bzw. intrazellulär agierenden Bakterien gehören auch die Chlamydien. In epidemiologischen Studien wurde in bis zu 15 % aller erfassten Pneumoniefälle Chlamydia pneumoniae identifiziert [1] [2] [3] [4] [5] [9] [10]. Gleichzeitig gelang jedoch häufig der Nachweis eines zweiten oder dritten Erregers im Sinne einer Mischinfektion, so dass die Frage nach der pathogenetischen Bedeutung von Chlamydia pneumoniae für die Pneumonie zum Teil sehr kontrovers diskutiert wurde [11] [12] [13]. Das derzeitige Hauptproblem und der Schwerpunkt in der Chlamydienforschung betrifft die Diagnostik dieser obligat intrazellulären, gramnegativen Bakterien [14]. Trotz einer Vielzahl von Nachweismethoden ist zur Zeit keine Technik in der Lage, einen schnellen und zugleich verlässlichen Erregernachweis zu erbringen. Zudem fehlt noch jegliche Standardisierung. Zur Therapie von Chlamydieninfektionen insbesondere der Pneumonie stehen sehr potente Antibiotika wie die Makrolide und das Azalid Azithromycin, das Ketolid Telithromycin, das Tetracyclin Doxycyclin und die Fluorochinolone der neuen Generation zur Verfügung.

Literatur

  • 1 Fang G, Fine M, Orloff J. et al . New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 356 cases.  Medicine. 1990;  69 307-316
    PubMedGoogle Scholar
  • 2 Mandall L A. Comunity-acquired pneumonia: etiology, epidemiology, and treatment.  Chest . 1995;  (suppl) 108 35-42
    PubMedGoogle Scholar
  • 3 Lode H, Steinhoff D, Schaberg T. et al . New pneumonia pathogens, especially Chlamydia pneumoniae and Hantaviruses.  Internist (Berl). 1996;  37 882-889
    PubMedGoogle Scholar
  • 4 Steinhoff D, Lode H, Ruckdeschel G. et al . Chlamydia pneumoniae as a cause of community-acquired pneumonia is hospitalised patients in Berlin.  Clin Infect Dis. 1996;  22 958-964
    PubMedGoogle Scholar
  • 5 Allewelt M, Steinhoff D, Rahlwes M. et al . Wandel im Erregerspektrum ambulant erworbener Pneumonien (1982 - 1992).  Dtsch Med Wschr. 1997;  122 1027-1032
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Plouffe J F. Importance of atypical pathogens of community-acquired pneumonia.  Clin Infect Dis. 2000;  (suppl) 31 35-39
    CrossrefPubMedGoogle Scholar
  • 7 Cosentini R, Tarsia P, Blasi F. et al . Community-acquired pneumonia: role of atypical organisms.  Monalde Arch Chest Dis. 2001;  56 527-534
    PubMedGoogle Scholar
  • 8 Gupta S K, Sarosi G A. The role of atypical pathogens in community-acquired pneumonia.  Med Clin North Am. 2001;  85 1349-1365
    CrossrefPubMedGoogle Scholar
  • 9 Marrie T J. Community-acquired pneumonia.  Clin Infect Dis. 1994;  18 501-515
    PubMedGoogle Scholar
  • 10 Bartlett J G, Mundy L M. Community-acquired pneumonia.  New Engl J Med. 1995;  333 1618-1624
    CrossrefPubMedGoogle Scholar
  • 11 Kauppinen M T, Saikku P, Kujala P. et al . Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia.  Thorax. 1996;  51 185-189
    CrossrefPubMedGoogle Scholar
  • 12 Lieberman D, Schlaeffer F, Boldur I. et al . Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients.  Thorax. 1996;  51 179-184
    CrossrefPubMedGoogle Scholar
  • 13 Lieberman D, Ben-Yaakov M, Lazarovich Z. et al . Chlamydia pneumoniae community-acquired pneumonia: a review of 62 hospitalized adult patients.  Infection. 1996;  24 109-114
    CrossrefPubMedGoogle Scholar
  • 14 Dowell S F, Peeling R W, Boman J. et al . Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada).  Clin Infec Dis. 2001;  33 492-503
    CrossrefPubMedGoogle Scholar
  • 15 Kuo C C, Jackson L A, Campbell L A. et al . Chlamydia pneumoniae (TWAR).  Clin Microbiol Rev. 1995;  8 451-461
    PubMedGoogle Scholar
  • 16 Schachter J, Stamm W E. Chlamydia. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. Washington, D.C.: 7th ed. Press 1999: 669-677
    Google Scholar
  • 17 Stephens R S. Chlamydia: intracellular biology, pathogenesis, and immunity. Washington, D.C.: American Society for Microbiology 1999
    Google Scholar
  • 18 Everett K DE, Bush R M, Andersen A A. Emended description of the order Chlamydiales, proposal of Parachlamydiaceae fam. Nov. and Simkaniaceae fam. Nov., each containing one monotypic genus, revised taxonomy of the family Chlamydiaceae, including a new genus and five new species, and standards for the identifications of organisms.  Int J Syst Bactiriol. 1999;  49 415-440
    PubMedGoogle Scholar
  • 19 Amann R, Springer N, Schönhuber W. et al . Obligate intracellular bacterial parasites of acanthamoebae related to Chlamydia spp.  Appl Environ Microbiol. 1997;  63 115-121
    PubMedGoogle Scholar
  • 20 Fritsche T R, Horn M, Wagner M. et al . Phylogenetic diversity among geographically dispersed Chlamydiales endosymbionts recovered from clinical and environmental isolates of Acanthamoeba spp.  Appl Environ Microbiol. 2000;  66 2613-2619
    CrossrefPubMedGoogle Scholar
  • 21 Horn M, Wagner M, Müller K D. et al . Neochlamydia hartmannellae gen. nov., sp. nov. (Parachlamydiaceae), an endoparasite of the amoeba Hartmanellae vermiformis.  Microbiology. 2000;  146 1231-1239
    PubMedGoogle Scholar
  • 22 Kahane S, Everett K D, Kimmel N. et al . Simkania negevensis strain ZT: growth, antigenic and genome characteristics.  Int J Syst Bacteriol. 1999;  49 815-820
    PubMedGoogle Scholar
  • 23 Grayston J T, Diwan V K, Cooney M. et al . Community- and hospital-acquired pneumonia associated with Chlamydia TWAR infection demonstrated serologically.  Arch Intern Med. 1989;  149 169-173
    CrossrefPubMedGoogle Scholar
  • 24 Grayston J T, Campbell L A, Kuo C C. et al . A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.  J Infect Dis. 1990;  161 618-625
    PubMedGoogle Scholar
  • 25 Chirgwin K, Roblin P M, Gelling M. et al . Infection with Chlamydia pneumoniae in Brooklyn.  J Infect Dis. 1991;  163 757-761
    PubMedGoogle Scholar
  • 26 Kauppinen M, Saikku P. Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment.  Clin Inf Dis. 1995;  (suppl) 3 244-252
    PubMedGoogle Scholar
  • 27 Suttithawil W, Wangroongsarb P, Naigowit P. et al . Chlamydia (Chlamydia) pneumoniae as a cause of community-acquired pneumonia in Thailand.  J Med Assoc Thai. 2001;  84 430-437
    PubMedGoogle Scholar
  • 28 Kese D, Cizman M, Marin J. et al . Chlamydia pneumoniae infections in patients with community-acquired pneumonia in Slovenia.  Scand J Inf Dis. 2002;  34 172-176
    PubMedGoogle Scholar
  • 29 Miyashita N, Fukano H, Okimoto N. et al . Clinical presentation of community-acquired pneumonia in adults.  Chest. 2002;  121 1776-1781
    CrossrefPubMedGoogle Scholar
  • 30 Hammerschlag M R. Chlamydia pneumoniae and the lung.  Eur Respir J. 2000;  16 1001-1007
    PubMedGoogle Scholar
  • 31 Beaty C D, Grayston J C, Wang S P. et al . Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1991;  144 1408-1410
    CrossrefPubMedGoogle Scholar
  • 32 Karnak D, Beder S. Treatment of Chlamydia pneumoniae infection and chronic obstructive pulmonary disease.  Expert Opin Pharmacother. 2002;  3 1461-1470
    CrossrefPubMedGoogle Scholar
  • 33 Kraft M. The role of bacterial infections in asthma.  Clin Chest Med. 2000;  21 301-313
    CrossrefPubMedGoogle Scholar
  • 34 Hertzen L von. Role of persitent infection in the control and severity of asthma: focus on Chlamydia pneumoniae.  Eur Respir J. 2001;  19 546-556
    PubMedGoogle Scholar
  • 35 Wong Y K, Gallagher P J, Ward M E. Chlamydia pneumoniae and atherosclerosis.  Heart. 1999;  81 232-238
    PubMedGoogle Scholar
  • 36 Campball L A, Kuo C C. Chlamydia pneumoniae pathogenesis.  J Med Microbiol. 2002;  51 623-625
    PubMedGoogle Scholar
  • 37 Kalayoglu M V, Libby P, Byrne G I. Chlamydia pneumoniae as an emerging risk factor in cardiovascular diseases.  JAMA. 2002;  288 2724-2731
    CrossrefPubMedGoogle Scholar
  • 38 Ngeh J, Anand V, Gupta S. Chlamydia pneumoniae and atherosklerosis - what we know and what we don't.  Clin Microbiol Infect. 2002;  8 2-13
    CrossrefPubMedGoogle Scholar
  • 39 Balin B J, Appelt D M. Role of infection in Alzheimer' disease.  J Am Osteopath Assoc. 2001;  (suppl) 12 1-6
    PubMedGoogle Scholar
  • 40 Yucesan C, Sriram S. Chlamydia pneumoniae infection of the central nervous system.  Curr Opin Neurol. 2001;  14 355-359
    CrossrefPubMedGoogle Scholar
  • 41 Saikku P, Wang S P, Kleemola M. et al . An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci.  J Infect Dis. 1985;  151 832-839
    PubMedGoogle Scholar
  • 42 Storey C, Lusher M, Yates P. et al . Evidence for Chlamydia pneumoniae of non-human origin.  J Gen Bacteriol. 1993;  139 2621-2626
    PubMedGoogle Scholar
  • 43 Forsey T, Darougar S, Treharne J D. Prevalence in human beings of antibodies to Chlamydia IOL-207, an atypical strain of chlamydia.  J Infect. 1986;  12 145-152
    PubMedGoogle Scholar
  • 44 Kanamoto Y, Ouchi K, Mizui M. et al . Prevalence of antibody to Chlamydia pneumoniae TWAR in Japan.  J Clin Microbiol. 1991;  29 816-818
    PubMedGoogle Scholar
  • 45 Marton A, Karolyi A, Szalka A. Prevalence of Chlamydia pneumoniae antibodies in Hungary.  Eur J Clin Microbiol Infect Dis. 1992;  11 139-142
    PubMedGoogle Scholar
  • 46 Montes M, Cilla G. High prevalence of Chlamydia pneumoniae infection in children and young adults in Spain.  Pediatr Infect Dis J. 1992;  11 972-973
    PubMedGoogle Scholar
  • 47 Grayston J T. Infections caused by Chlamydia pneumoniae strain TWAR.  Clin Inf Dis. 1992;  15 757-763
    PubMedGoogle Scholar
  • 48 Grayston J T, Diwan V K, Cooney M. et al . Community- and hospital-acquired pneumonia associated with Chlamydia TWAR infection demonstrated serologically.  Arch Intern Med. 1989;  149 169-173
    CrossrefPubMedGoogle Scholar
  • 49 Cosentini R, Blasi F, Rossi S. et al .Chlamydia pneumoniae and severe community-acquired pneumonia. In: Orfila J, Byrne GI, Cherneskey MA, Grayston JT, et al. eds. Chlamydial infections - 1994. Bologna, Italy: Societa Editrice Esculapio 1994: 453-456
    Google Scholar
  • 50 Gaydos C A, Eiden J J, Oldach D. et al . Diagnosis of Chlamydia pneumoniae in patients with community-acquired pneumonia by polymerase chain reaction enzyme immunoassay.  Clin Infect Dis. 1994;  19 157-160
    CrossrefPubMedGoogle Scholar
  • 51 Kauppinen M, Kujala P, Leinonen M. et al .Clinical features of community-acquired Chlamydia pneumoniae pneumonia. In: Orfila J, Byrne GI, Cherneskey MA, et al. eds. Chlamydial infections - 1994. Bologna, Italy: Societa Editrice Esculapio 1994: 457-460
    Google Scholar
  • 52 Wainwright A P, Beaumont A C, Kox W J. Psittacosis: diagnosis and management of severe pneumonia and multi organ failure.  Intensive Care Med. 1987;  13 419-421
    PubMedGoogle Scholar
  • 53 Gregory D W, Schaffner W. Psittacosis.  Semin Respir Infect. 1997;  12 7-11
    PubMedGoogle Scholar
  • 54 Elliott J H. Psittacosis. A flu like syndrome.  Aust Fam Physician. 2001;  30 739-741
    PubMedGoogle Scholar
  • 55 Cles L D, Stamm W E. Use of HL cells for improved isolation and passage of Chlamydia pneumoniae.  J Clin Microbiol. 1990;  28 938-940
    PubMedGoogle Scholar
  • 56 Kuo C C, Grayston J T. A sensitive cell line, HL cells, for isolation and propagation of Chlamydia pneumoniae strain TWAR.  J Inf Dis. 1990;  162 755-758
    PubMedGoogle Scholar
  • 57 Wong K H, Skelton S K, Chan Y K. Efficient culture of chlamydia pneumoniae with cell lines derived from the human respiratory tract.  J Clin Microbiol. 1992;  30 1625-1630
    PubMedGoogle Scholar
  • 58 Grayston J T, Kuo C C, Wang S P. et al . A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infection.  N Engl J Med. 1986;  315 161-168
    PubMedGoogle Scholar
  • 59 Kuo C C, Chen H H, Wang S P. et al . Identification of a new group of Chlamydia psittaci strains called TWAR.  J Clin Microbiol. 1986;  24 1034-1037
    PubMedGoogle Scholar
  • 60 Person K, Haidl S. Evaluation of a commercial test for antibodies to the chlamydial lipopolysaccharide (Medac) for serodiagnosis of acute infections by Chlamydia pneumoniae (TWAR) and Chlamydia psittaci.  APMIS. 2000;  108 131-138
    CrossrefPubMedGoogle Scholar
  • 61 Johnsen S, Andersen P L, Stanek G. et al . Chlamydia antibody response in healthy volunteers immunized with nonchlamydial antigens: a randomized, double-blind, placebo-controlled study.  Clin Inf Dis. 2003;  36 586-591
    CrossrefPubMedGoogle Scholar
  • 62 Nurminen M, Leinonen M, Saikku P. et al . The genus-specific antigen of Chlamydia: resemblance to the lipopolysaccharide of enteric bacteria.  Science. 1983;  220 1279-1281
    PubMedGoogle Scholar
  • 63 Peeling R. Chlamydia pneumoniae infections: applications of laboratory methods. In: Allegra L, Blasi F, eds. Chlamydia pneumoniae: the lung and the heart. Milano: Springer-Verlag Italia 1999: 33-42
    Google Scholar
  • 64 Wang S. Serology for Chlamydia pneumoniae (TWAR). In: Allegra L, Blasi F, eds. Chlamydia pneumoniae: the lung and the heart. Milano: Springer-Verlag Italia 1999: 16-23
    Google Scholar
  • 65 Wang S P, Grayston J T. Immunologic relationship between genital TRIC, lymphogranuloma venereum, and related organisms in a new microtiter indirect immunofluorescence test.  Am J Ophthal. 1970;  70 367-374
    PubMedGoogle Scholar
  • 66 Schachter J. Chlamydiae. In: Rose NR, DeMarcario EC, Fahey JL, Friedman H, Pen GM, eds. Manual of clinical laboratory immunology. Washington, D.C.: 4th ed. American Society for Microbiology 1992: 661-666
    Google Scholar
  • 67 Ekman M R, Leinonen M, Syrjala H. et al . Evaluation of serological methods in the diagnosis of Chlamydia pneumoniae pneumonia during an epidemic in Finland.  Eur J Clin Microbiol Infect Dis. 1993;  12 756-760
    PubMedGoogle Scholar
  • 68 Verkooyen R P, Lent N A van, Mousavi Joulandan S A. et al . Diagnosis of Chlamydia pneumoniae in fection in patients with chronic obstructive pulmonary diseases by microimmunofluorescence and ELISA.  J Med Microbiol. 1997;  46 959-964
    PubMedGoogle Scholar
  • 69 Verkooyen R P, Willemse D, Hiep-van Casteren S CAM. et al . Evaluation of PCR, culture, and serology for diagnosis of Chlamydia pneumoniae respiratory infections.  J Clin Microbiol. 1998;  36 2301-2307
    PubMedGoogle Scholar
  • 70 Peeling R W, Wang S P, Grayston J T. et al . Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results.  J Inf Dis. 2000;  (suppl) 181 426-429
    PubMedGoogle Scholar
  • 71 Messmer T O, Martinez J, Hassouna F. et al . Comparison of two commercial microimmunofluorescence kits for detection of serum immunoglobulin G antibodies to Chlamydia pneumoniae.  Clin Diagn Lab Immunol. 2001;  8 588-592
    CrossrefPubMedGoogle Scholar
  • 72 Hermann C, Graf K, Groh A. et al . Comparison of eleven commercial tests for Chlamydia pneumoniae-specific immunoglobulin G in asymptomatic healthy individuals.  J Clin Microbiol. 2002;  40 1603-1609
    CrossrefPubMedGoogle Scholar
  • 73 Tugwell P, Dennis D T, Weinstein A. et al . Laboratory evaluation in the diagnosis of Lyme disease.  Ann Intern Med. 1997;  127 1109-1123
    PubMedGoogle Scholar
  • 74 Bas S, Muzzin P, Ninet B. et al . Chlamydial serology: comparative diagnostic value of immunoblotting, microimmunofluorescence test, and immunoassays using different recombinant proteins as antigens.  J Clin Microbiol. 2001;  39 1368-1377
    CrossrefPubMedGoogle Scholar
  • 75 Boman J, Allard A, Persson K. et al . Rapid diagnosis of respiratory Chlamydia pneumoniae infection by nested touchdown polymerase chain reaction compared with culture and antigen detection by EIA.  J Infect Dis. 1997;  175 1523-1526
    PubMedGoogle Scholar
  • 76 Tong C, Sillis M. Detection of Chlamydia pneumoniae and Chlamydia psittaci in sputum samples by PCR.  J Clin Pathol. 1993;  46 313-317
    PubMedGoogle Scholar
  • 77 Campbell L A, Melgosa M P, Hamilton D J. et al . Detection of Chlamydia pneumoniae by polymerase chain reaction.  J Clin Microbiol. 1992;  30 434-439
    PubMedGoogle Scholar
  • 78 Gaydos C A, Roblin P M, Hammerschlag M R. et al . Diagnostic utility of PCR-enzyme immunoassay, culture and serology for detection of Chlamydia pneumoniae in symptomatic and asymptomatic patients.  J Clin Microbiol. 1994;  32 903-905
    PubMedGoogle Scholar
  • 79 Hyman C L, Roblin P M, Gaydos C A. et al . Prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: assessment by polymerase chain reaction-enzyme immunoassay and culture.  Clin Infect Dis. 1995;  20 1174-1178
    PubMedGoogle Scholar
  • 80 Mygind T, Birkelund S, Birkebaek N. et al . Determination of PCR efficiency in chelex-100 purified clinic samples and comparison of real-time quantitative PCR and conventional PCR for detection of Chlamydia pneumoniae.  BMC Microbiol. 2002;  9 17
    PubMedGoogle Scholar
  • 81 Tondella M L, Talkington D F, Holloway B P. et al . Development and evaluation of real-time PCR-based fluorescence assays for detection of Chlamydia pneumoniae.  J Clin Microbiol. 2002;  40 575-583
    CrossrefPubMedGoogle Scholar
  • 82 Kuoppa Y, Boman J, Scott L. et al . Quantitative detection of respiratory Chlamydia pneumoniae infection by real-time PCR.  J Clin Microbiol. 2002;  40 2273-2274
    CrossrefPubMedGoogle Scholar
  • 83 Apfalter P, Barousch W, Nehr M. et al . Comparison of a new quantitative ompA-based real-time PCR TaqMan assay for detection of Chlamydia pneumoniae DNA in respiratory specimens with four conventional PCR assays.  J Clin Microbiol. 2003;  41 592-600
    CrossrefPubMedGoogle Scholar
  • 84 Reischl U, Lehne N, Simnacher U. et al . Rapid and standized detection of Chlamydia pneumoniae using LightCycler real-time fluorescence PCR.  Eur J Clin Microbiol Infect Dis. 2003;  22 54-57
    PubMedGoogle Scholar
  • 85 Welti M, Jaton K, Altwegg M. et al . Development of a multiplex real-time quantitative PCR assay to detect Chlamydia pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae in respiratory tract secretions.  Diagn Microbiol Infect Dis. 2003;  45 85-95
    CrossrefPubMedGoogle Scholar
  • 86 Poppert S, Essig A, Marre R. et al . Detection and differentiation of Chlamydiae by fluorescence in situ hybridization.  Appl Environ Microbiol. 2002;  68 4081-4089
    CrossrefPubMedGoogle Scholar
  • 87 Niedermann M S, Mandell L A, Anzueto A. et al . Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, initial antimicrobial therapy, and prevention.  Am J Respir Crit Care Med. 2001;  148 1730-1754
    PubMedGoogle Scholar
  • 88 Schaberg T, Dalhoff K, Ewig S. et al . Deutsche Gesellschaft für Pneumologie. Empfehlungen zur Therapie der ambulant erworbenen Pneumonie.  Pneumologie. 1998;  51 450-462
    PubMedGoogle Scholar
  • 89 Bartlett J G, Dowell F S, Mandell L A. et al . Practice guidelines for the management of community acquired pneumonia in adults.  Clin Inf Dis. 2000;  31 347-382
    CrossrefPubMedGoogle Scholar
  • 90 Mandall L A, Marrie T J, Grossman R F. et al . Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society.  Clin Infect Dis. 2000;  31 383-421
    CrossrefPubMedGoogle Scholar
  • 91 Hammerschlag M R. Antimicrobial susceptibility and therapy of infections caused Chlamydia pneumoniae.  Antimicrob Agents Chemother. 1994;  38 1873-1878
    PubMedGoogle Scholar
  • 92 Roblin P M, Kutlin A, Hammerschlag M R. In vitro activity of trovafloxacin against Chlamydia pneumoniae.  Antimicrob Agents Chemother. 1997;  41 2033-2034
    PubMedGoogle Scholar
  • 93 Roblin P M, Hammerschlag M R. In vitro activity of a new 8-methoxyquinolone, BAY 12 - 8039, against Chlamydia pneumoniae.  Antimicrob Agents Chemother. 1998;  42 951-952
    PubMedGoogle Scholar
  • 94 Hammerschlag M R, Qumei K K, Roblin P M. In vitro activities of azithromycin, clarithromycin, L-ofloxacin and other antibiotics against Chlamydia pneumoniae.  Antimicrob Agents Chemother. 1992;  36 1573-1574
    PubMedGoogle Scholar
  • 95 Ridgway G L, Salman H, Robbins M J. et al . In-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.  J Antimicrob Chemother. 1997;  (suppl) 40 31-34
    PubMedGoogle Scholar
  • 96 Miyashita N, Niki Y, Kishimoto T. et al . In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.  Antimicrob Agents Chemother. 1997;  41 1331-1334
    PubMedGoogle Scholar
  • 97 Donati M, Rodriguez Fermepin M, Olmo A. et al . Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp.  J Antimicrob Chemother. 1999;  43 825-827
    CrossrefPubMedGoogle Scholar
  • 98 Kimura M, Kishimoto T, Niki Y. et al . In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents.  Antimicrob Agents Chemother. 1993;  37 801-803
    PubMedGoogle Scholar
  • 99 Roblin P M, Kutlin A, Reznik T. et al . Activity of grepafloxacin and other fluoroquinolones and newer macrolides against recent clinical isolates of Chlamydia pneumoniae.  Int J Antimicrob Agents. 1999;  12 181-184
    PubMedGoogle Scholar
  • 100 Roblin P M, Hammerschlag M R. In vitro activity of Gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae.  J Antimicrob Chemother. 1999;  44 549-551
    CrossrefPubMedGoogle Scholar
  • 101 Roblin P M, Reznik T, Kutlin A. et al . In vitro activities of gemifloxacin (SB-265 805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.  Antimicrob Agents Chemother. 1999;  43 2806-2807
    PubMedGoogle Scholar
  • 102 Block S, Hedrick J, Hammerschlag M R. et al . Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia; comparative efficacy and safety of clarithromycin vs erythromycin ethylsuccinate.  Pediatr Infect Dis J. 1995;  14 471-477
    CrossrefPubMedGoogle Scholar
  • 103 Roblin P M, Hammerschlag M R. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired peumonia.  Antimicrob Agents Chemother. 1998;  42 194-196
    PubMedGoogle Scholar
  • 104 Balfour J A, Figgitt D P. Telithromycin.  Drugs. 2001;  61 815-829
    PubMedGoogle Scholar
  • 105 Roblin P M, Hammerschlag M R. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.  Antimicrob Agents Chemother. 1998;  42 1515-1516
    PubMedGoogle Scholar
  • 106 Strigl S, Robin P M, Reznik T. et al . In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae.  Antimicrob Agents Chemother. 2000;  44 1112-1113
    CrossrefPubMedGoogle Scholar
  • 107 Dessus-Babus S, Bebear C M, Charron A. et al . Sequencing of gyrase and topoisomerase IV quinolone-resistence-determining regions of Chlamydia trachomatis and characterization of quinolon-resistent mutants obtained in vitro.  Antimicrob Agents Chemother. 1998;  42 1474-2481
    PubMedGoogle Scholar
  • 108 Hammerschlag M R. Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review.  J Antimicrob Chemother. 2000;  (suppl) 45 35-39
    PubMedGoogle Scholar
  • 109 Hammerschlag M R, Hyman C L, Roblin P M. In vitro activities of five quinolones against Chlamydia pneumoniae.  Antimicrob Agents Chemother. 1992;  36 682-683
    PubMedGoogle Scholar
  • 110 Woodcock J M, Andrews J M, Boswell F J. et al . In vitro activity of BAY 12 - 8039, a new fluoroquinolone.  Antimicrob Agents Chemother. 1997;  41 101-106
    PubMedGoogle Scholar
  • 111 Wise R, Andrews J M, Brenwald N. The in-vitro activity of OPC-17 116, a new 5-methyl substituted quinolone.  J Antimicrob Chemother. 1993;  31 497-504
    PubMedGoogle Scholar
  • 112 Roblin P M, Montalban G, Hammerschlag M R. In vitro activities of OPC-17 116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.  Antimicrob Agents Chemother. 1994;  38 1402-1403
    PubMedGoogle Scholar
  • 113 Plouffe J F, Herbert M T, File jr T M. et al . Ofloxacin versus standard therapy in treatment of community-acqired pneumonia requiring hospitalization. Pneumonia Study Group.  Antimicrob Agents Chemother. 1996;  40 1175-1179
    PubMedGoogle Scholar
  • 114 File jr T M, Segreti J, Dunbar L. et al . A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.  Antimicrob Agents Chemother. 1997;  41 1965-1972
    PubMedGoogle Scholar

Priv.-Doz. Dr. med. T. Welte

Otto-von-Guericke-Universität Magdeburg, Medizinische Fakultät · Abteilung für Pneumologie und Internistische Intensivtherapie

Leipziger Straße 44

39120 Magdeburg

Email: tobias.welte@medizin.uni-magdeburg.de

      >